Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | CTSV | O60911 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25881437 | 0.78 | CTSK (0.43) | CTSKCTSVCTSS | |
| SCHEMBL25877171 | 0.76 | AKT1 (0.40) | CTSK | |
| SCHEMBL25881412 | 0.73 | CTSK (0.38) | CTSKCTSVCTSS | |
| SCHEMBL14870493 | 0.70 | CTSV (0.38) | CTSKCTSVCTSLCTSBELANE | |
| SCHEMBL24690951 | 0.70 | CTSV (0.50) | CTSKCTSVCTSS | |
| SCHEMBL16867326 | 0.70 | ELANE (0.55) | CTSKCTSVCTSLCTSBELANE | |
| SCHEMBL24961108 | 0.70 | CTSV (0.50) | CTSKCTSVCTSS | |
| SCHEMBL25877198 | 0.69 | CNR2 (0.42) | HDAC1 | |
| SCHEMBL27349036 | 0.69 | ELANE (0.39) | CTSKCTSVCTSLCTSBELANE | |
| SCHEMBL25881278 | 0.69 | CTSV (0.42) | CTSKCTSVCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234921-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234921-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | SERPINB1, CTSV, CTSE | HDAC1 1112/4885CTSK 48/4885NAMPT 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.